Cargando…

Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is a largely incurable disease and an emerging problem in aging societies. It occurs in two forms, dry and wet (exudative, neovascular), which may cause legal blindness and sight loss. Currently, there is not any effective treatment for dry AMD. Meanwhile, repe...

Descripción completa

Detalles Bibliográficos
Autores principales: Blasiak, Janusz, Chojnacki, Jan, Szczepanska, Joanna, Fila, Michal, Chojnacki, Cezary, Kaarniranta, Kai, Pawlowska, Elzbieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421466/
https://www.ncbi.nlm.nih.gov/pubmed/37571296
http://dx.doi.org/10.3390/nu15153358
_version_ 1785088987364327424
author Blasiak, Janusz
Chojnacki, Jan
Szczepanska, Joanna
Fila, Michal
Chojnacki, Cezary
Kaarniranta, Kai
Pawlowska, Elzbieta
author_facet Blasiak, Janusz
Chojnacki, Jan
Szczepanska, Joanna
Fila, Michal
Chojnacki, Cezary
Kaarniranta, Kai
Pawlowska, Elzbieta
author_sort Blasiak, Janusz
collection PubMed
description Age-related macular degeneration (AMD) is a largely incurable disease and an emerging problem in aging societies. It occurs in two forms, dry and wet (exudative, neovascular), which may cause legal blindness and sight loss. Currently, there is not any effective treatment for dry AMD. Meanwhile, repeated intravitreal injections with antibodies effective against vascular endothelial growth factor A (VEGFA) slow down wet AMD progression but are not free from complications. (-)-Epigallocatechin-3-gallate (EGCG) is an active compound of green tea, which exerts many beneficial effects in the retinal pigment epithelium and the neural retina. It has been reported to downregulate the VEGFA gene by suppressing its activators. The inhibition of mitogen-activated protein kinases 1 and 3 (MAPK1 and MAPK3) may lie behind the antiangiogenic action of EGCG mediated by VEGFA. EGCG exerts protective effects against UV-induced damage to retinal cells and improves dysfunctional autophagy. EGCG may also interact with the mechanistic target rapamycin (MTOR) and unc-51-like autophagy activating kinase (ULK1) to modulate the interplay between autophagy and apoptosis. Several other studies report beneficial effects of EGCG on the retina that may be related to wet AMD. Therefore, controlled clinical trials are needed to verify whether diet supplementation with EGCG or green tea consumption may improve the results of anti-VEGFA therapy in wet AMD.
format Online
Article
Text
id pubmed-10421466
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104214662023-08-12 Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration Blasiak, Janusz Chojnacki, Jan Szczepanska, Joanna Fila, Michal Chojnacki, Cezary Kaarniranta, Kai Pawlowska, Elzbieta Nutrients Review Age-related macular degeneration (AMD) is a largely incurable disease and an emerging problem in aging societies. It occurs in two forms, dry and wet (exudative, neovascular), which may cause legal blindness and sight loss. Currently, there is not any effective treatment for dry AMD. Meanwhile, repeated intravitreal injections with antibodies effective against vascular endothelial growth factor A (VEGFA) slow down wet AMD progression but are not free from complications. (-)-Epigallocatechin-3-gallate (EGCG) is an active compound of green tea, which exerts many beneficial effects in the retinal pigment epithelium and the neural retina. It has been reported to downregulate the VEGFA gene by suppressing its activators. The inhibition of mitogen-activated protein kinases 1 and 3 (MAPK1 and MAPK3) may lie behind the antiangiogenic action of EGCG mediated by VEGFA. EGCG exerts protective effects against UV-induced damage to retinal cells and improves dysfunctional autophagy. EGCG may also interact with the mechanistic target rapamycin (MTOR) and unc-51-like autophagy activating kinase (ULK1) to modulate the interplay between autophagy and apoptosis. Several other studies report beneficial effects of EGCG on the retina that may be related to wet AMD. Therefore, controlled clinical trials are needed to verify whether diet supplementation with EGCG or green tea consumption may improve the results of anti-VEGFA therapy in wet AMD. MDPI 2023-07-28 /pmc/articles/PMC10421466/ /pubmed/37571296 http://dx.doi.org/10.3390/nu15153358 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Blasiak, Janusz
Chojnacki, Jan
Szczepanska, Joanna
Fila, Michal
Chojnacki, Cezary
Kaarniranta, Kai
Pawlowska, Elzbieta
Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
title Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
title_full Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
title_fullStr Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
title_full_unstemmed Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
title_short Epigallocatechin-3-Gallate, an Active Green Tea Component to Support Anti-VEGFA Therapy in Wet Age-Related Macular Degeneration
title_sort epigallocatechin-3-gallate, an active green tea component to support anti-vegfa therapy in wet age-related macular degeneration
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10421466/
https://www.ncbi.nlm.nih.gov/pubmed/37571296
http://dx.doi.org/10.3390/nu15153358
work_keys_str_mv AT blasiakjanusz epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration
AT chojnackijan epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration
AT szczepanskajoanna epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration
AT filamichal epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration
AT chojnackicezary epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration
AT kaarnirantakai epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration
AT pawlowskaelzbieta epigallocatechin3gallateanactivegreenteacomponenttosupportantivegfatherapyinwetagerelatedmaculardegeneration